Characterization and treatment of resistant hypertension

Current Cardiology Reports

Volumn 11, Issue 6, 2009, Pages 407-413

  Pisoni, Roberto ^a   Ahmed, Mustafa I ^b   Calhoun, David A ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BUMETANIDE; CARVEDILOL; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; METHYLDOPA; MINOXIDIL; SPIRONOLACTONE;

ALCOHOL CONSUMPTION; ALDOSTERONE BLOOD LEVEL; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CUSHING SYNDROME; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; EXERCISE; FLUID RETENTION; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; KIDNEY ARTERY STENOSIS; LIFESTYLE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; OBESITY; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SALT INTAKE; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING CESSATION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TACHYCARDIA; WHITE COAT HYPERTENSION;

ADRENAL GLAND NEOPLASMS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIFE STYLE; OBESITY; PHEOCHROMOCYTOMA; PITUITARY ACTH HYPERSECRETION; PREVALENCE; PROGNOSIS; RENAL ARTERY OBSTRUCTION; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT FAILURE; UNITED STATES;

EID: 72849129695     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0059-z     Document Type: Review

References (45)

1. D.A. Calhoun D. Jones S. Textor, et al. 2008 Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research Circulation 117 e510 e526 10.1161/CIRCULATIONAHA.108.189141 18574054
2. A.V. Chobanian G.L. Bakris H.R. Black, et al. 2003 Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure Hypertension 42 1206 1252 10.1161/01.HYP.0000107251.49515.c2 1:CAS:528:DC%2BD3sXpsVGisL4%3D 14656957 (Pubitemid 37553153)
3. W.C. Cushman C.E. Ford J.A. Cutler, et al. 2002 Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 4 393 404 10.1111/j.1524-6175.2001.01481.x
4. C.J. Pepine E.M. Handberg R.M. Cooper-DeHoff, et al. 2003 A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial JAMA 290 2805 2816 10.1001/jama.290.21.2805 1:CAS:528:DC%2BD3sXps1Crurk%3D 14657064 (Pubitemid 37509488)
5. C. Cuspidi G. Macca L. Sampieri, et al. 2001 High prevalence of cardiac and extracardiac target organ damage in refractory hypertension J Hypertens 19 2063 2070 10.1097/00004872-200111000-00018 1:CAS:528:DC%2BD3MXotlCju70%3D 11677373 (Pubitemid 33035812)
6. S. Lewington R. Clarke N. Qizilbash, et al. 2002 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903 1913 10.1016/S0140-6736(02)11911-8 12493255 (Pubitemid 35472129)
7. G.F. Salles C.R. Cardoso E.S. Muxfeldt 2008 Prognostic influence of office and ambulatory blood pressures in resistant hypertension Arch Intern Med 168 2340 2346 10.1001/archinte.168.21.2340 19029499
8. E.S. Muxfeldt C.R. Cardoso G.F. Salles 2009 Prognostic value of nocturnal blood pressure reduction in resistant hypertension Arch Intern Med 169 874 880 10.1001/archinternmed.2009.68 19433699
9. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg [no authors listed]. JAMA 1967, 202:1028-1034.
10. D.M. Lloyd-Jones J.C. Evans M.G. Larson, et al. 2000 Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community Hypertension 36 594 599 1:STN:280: DC%2BD3cvpvFGnsQ%3D%3D 11040241
11. K.K. Gaddam M.K. Nishizaka M.N. Pratt-Ubunama, et al. 2008 Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion Arch Intern Med 168 1159 1164 10.1001/archinte.168.11.1159 1:CAS:528: DC%2BD1cXnvVSksrg%3D 18541823 (Pubitemid 351831398)
12. C.C. Gonzaga D.A. Calhoun 2008 Resistant hypertension and hyperaldosteronism Curr Hypertens Rep 10 496 503 10.1007/s11906-008-0092-0 1:CAS:528:DC%2BD1MXhsF2ru7Y%3D 18959838
13. M. Moser J.F. Setaro 2006 Clinical practice. Resistant or difficult-to-control hypertension N Engl J Med 355 385 392 10.1056/NEJMcp041698 1:CAS:528:DC%2BD28XntlSjuro%3D 16870917 (Pubitemid 44127541)
14. S.D. Pierdomenico D. Lapenna A. Bucci, et al. 2005 Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension Am J Hypertens 18 1422 1428 10.1016/j.amjhyper.2005. 05.014 16280275 (Pubitemid 41566669)
15. G.M. Singer M. Izhar H.R. Black 2002 Goal-oriented hypertension management: translating clinical trials to practice Hypertension 40 464 469 10.1161/01.HYP.0000035858.04434.03 1:CAS:528:DC%2BD38XntlamsL4%3D 12364348
16. S.A. Oliveria P. Lapuerta B.D. McCarthy, et al. 2002 Physicianrelated barriers to the effective management of uncontrolled hypertension Arch Intern Med 162 413 420 10.1001/archinte.162.4.413 11863473
17. N. Boudville S. Ward M. Benaroia A.A. House 2005 Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease Am J Hypertens 18 1300 1305 10.1016/j.amjhyper.2004.08.031 1:CAS:528:DC%2BD2MXhtVymsrfF 16202852 (Pubitemid 41400198)
18. F.W. Ashley Jr W.B. Kannel 1974 Relation of weight change to changes in atherogenic traits: the Framingham study J Chronic Dis 27 103 114 10.1016/0021-9681(74)90079-4 4830839
19. M. Modan S. Almog Z. Fuchs, et al. 1991 Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs Hypertension 17 565 573 1:STN:280:DyaK3M7pt12jsw%3D%3D 2013483
20. L. Mosso C. Carvajal A. Gonzalez, et al. 2003 Primary aldosteronism and hypertensive disease Hypertension 42 161 165 10.1161/01.HYP.0000079505.25750.11 1:CAS:528:DC%2BD3sXls1ajt7g%3D 12796282 (Pubitemid 36944590)
21. D.A. Calhoun M.K. Nishizaka M.A. Zaman, et al. 2002 Hyperaldosteronism among black and white subjects with resistant hypertension Hypertension 40 892 896 10.1161/01.HYP.0000040261.30455.B6 1:CAS:528:DC%2BD38XovFKnsLg%3D 12468575 (Pubitemid 35434912)
22. V.M. Campese N. Mitra D. Sandee 2006 Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 69 967 973 10.1038/sj.ki.5000177 1:CAS:528:DC%2BD28XitFGhtL4%3D 16528245 (Pubitemid 43372170)
23. A.S. Levey J. Coresh E. Balk, et al. 2003 National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Ann Intern Med 139 137 147 12859163
24. J.P. Casas W. Chua S. Loukogeorgakis, et al. 2005 Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 366 2026 2033 10.1016/S0140-6736(05)67814-2 1:CAS:528:DC%2BD2MXht12ku7nJ 16338452 (Pubitemid 41773378)
25. L. Grote J. Hedner J.H. Peter 2000 Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension J Hypertens 18 679 685 10.1097/00004872-200018060-00004 1:STN:280:DC%2BD3cvotlWktQ%3D%3D 10872551
26. P. Lavie V. Hoffstein 2001 Sleep apnea syndrome: a possible contributing factor to resistant Sleep 24 721 725 1:STN:280:DC%2BD3Mrht1Gnuw%3D%3D 11560187
27. A.G. Logan S.M. Perlikowski A. Mente, et al. 2001 High prevalence of unrecognized sleep apnoea in drug-resistant hypertension J Hypertens 19 2271 2277 10.1097/00004872-200112000-00022 1:CAS:528:DC%2BD3MXpt1CmsLY%3D 11725173 (Pubitemid 33135251)
28. M.N. Pratt-Ubunama M.K. Nishizaka R.L. Boedefeld, et al. 2007 Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension Chest 131 453 459 10.1378/chest.06-1442 1:CAS:528:DC%2BD2sXjtlWqt74%3D 17296647 (Pubitemid 46298490)
29. G.V. Robinson J.R. Stradling R.J. Davies 2004 Sleep. 6: Obstructive sleep apnoea/hypopnoea syndrome and hypertension Thorax 59 1089 1094 10.1136/thx.2003.015875 1:STN:280:DC%2BD2cnhtlWntA%3D%3D 15563710 (Pubitemid 39573930)
30. J.W. Lenders G. Eisenhofer M. Mannelli K. Pacak 2005 Phaeochromocytoma Lancet 366 665 675 10.1016/S0140-6736(05)67139-5 16112304 (Pubitemid 41176020)
31. J.P. Garg W.J. Elliott A. Folker, et al. 2005 Resistant hypertension revisited: a comparison of two university-based cohorts Am J Hypertens 18 619 626 10.1016/j.amjhyper.2004.11.021 15882544 (Pubitemid 40692429)
32. R.C. Hermida D.E. Ayala J.R. Fernandez C. Calvo 2008 Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension Hypertension 51 69 76 10.1161/HYPERTENSIONAHA.107. 096933 1:CAS:528:DC%2BD2sXhsVagurnI 17968001 (Pubitemid 350307106)
33. K. Jamerson M.A. Weber G.L. Bakris, et al. 2008 Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2417 2428 10.1056/NEJMoa0806182 1:CAS:528:DC%2BD1cXhsVCrurjJ 19052124
34. M.E. Ernst B.L. Carter C.J. Goerdt, et al. 2006 Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure Hypertension 47 352 358 10.1161/01.HYP.0000203309. 07140.d3 1:CAS:528:DC%2BD28Xht1Cmtrk%3D 16432050 (Pubitemid 43740274)
35. ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group. The AntihypertensiveLipid-Lowering Treatment to Prevent Heart Attack Trial 2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT) JAMA 288 2981 2997 10.1001/jama.288.23.2981 (Pubitemid 35471160)
36. M.K. Nishizaka M.A. Zaman D.A. Calhoun 2003 Efficacy of lowdose spironolactone in subjects with resistant hypertension Am J Hypertens 16 925 930 10.1016/S0895-7061(03)01032-X 1:CAS:528:DC%2BD3sXot1Omsbk%3D 14573330 (Pubitemid 37315491)
37. I.K. Eide P.A. Torjesen A. Drolsum, et al. 2004 Low-renin status in therapy-resistant hypertension: a clue to efficient treatment J Hypertens 22 2217 2226 10.1097/00004872-200411000-00026 1:CAS:528:DC%2BD2cXotlagu7o%3D 15480108 (Pubitemid 39463817)
38. R.R. Townsend D.J. DiPette R. Goodman, et al. 1990 Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients Clin Pharmacol Ther 48 665 675 1:STN:280: DyaK3M%2FmsV2jsg%3D%3D 2249378
39. E. Rodilla J.A. Costa F. Perez-Lahiguera, et al. 2009 Spironolactone and doxazosin treatment in patients with resistant hypertension Rev Esp Cardiol 62 158 166 10.1016/S1885-5857(09)71534-8 19232189
40. G.S. Stergiou T. Makris M. Papavasiliou, et al. 2005 Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy J Hypertens 23 883 889 10.1097/01.hjh.0000163159.22116.ab 1:CAS:528:DC%2BD2MXitlOmu74%3D 15775795
41. S. Yusuf K.K. Teo J. Pogue, et al. 2008 Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 1547 1559 10.1056/NEJMoa0801317 1:CAS:528:DC%2BD1cXksF2isLs%3D 18378520
42. J.F. Mann R.E. Schmieder M. McQueen, et al. 2008 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547 553 10.1016/S0140-6736(08)61236-2 1:CAS:528:DC%2BD1cXpvFKgsLs%3D 18707986
43. S. Oparil S.A. Yarows S. Patel, et al. 2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Lancet 370 221 229 10.1016/S0140-6736(07)61124-6 1:CAS:528:DC%2BD2sXnvF2gsrc%3D 17658393 (Pubitemid 47069535)
44. H. Krum M. Schlaich R. Whitbourn, et al. 2009 Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 1275 1281 10.1016/S0140-6736(09) 60566-3 19332353
45. K.A. Illig M. Levy L. Sanchez, et al. 2006 An implantable carotid sinus stimulator for drug-resistant hypertension: Surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial J Vasc Surg 44 1213 1218 10.1016/j.jvs.2006.08.024 17145423 (Pubitemid 44828412)